Pharmacologic Ppar-Gamma Activation Reprograms Bone Marrow Macrophages And Partially Rescues Hspc Mobilization In Human And Murine Diabetes

Mobilization of hematopoietic stem/progenitor cells (HSPC) from the bone marrow (BM) is impaired in diabetes. Excess oncostatin M (OSM) produced by M1 macrophages in the diabetic BM signals through p66Shc to induceCxcl12in stromal cells and retain HSPC. BM adipocytes are another source of CXCL12 that blunts mobilization. We tested a strategy of pharmacologic macrophage reprogramming to rescue HSPC mobilization. In vitro, PPAR-gamma activation with pioglitazone switched macrophages from M1 to M2, reducedOsmexpression, and prevented transcellular induction ofCxcl12. In diabetic mice, pioglitazone treatment downregulatedOsm,p66Shc, andCxcl12in the hematopoietic BM, restored the effects of granulocyte-colony stimulation factor (G-CSF), and partially rescued HSPC mobilization, but it increased BM adipocytes.Osmdeletion recapitulated the effects of pioglitazone on adipogenesis, which was p66Shc independent, and double knockout of Osm and p66Shc completely rescued HSPC mobilization. In the absence of OSM, BM adipocytes produced less CXCL12, being arguably devoid of HSPC-retaining activity, whereas pioglitazone failed to downregulateCxcl12in BM adipocytes. In patients with diabetes on pioglitazone therapy, HSPC mobilization after G-CSF was partially rescued. In summary, pioglitazone reprogrammed BM macrophages and suppressed OSM signaling, but sustainedCxcl12expression by BM adipocytes could limit full recovery of HSPC mobilization.